Loading... Please wait...
Sort by:


dossier-jpg.jpgDossier 
reports present unbiased and concise analysis based on interviews with leading industry experts on important trends and challenging issues affecting the pharma industry today. 

  • Real World Data: Meeting Payer Needs
    Learn More Real World Data: Meeting Payer Needs
    How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...
  • How Payers Want to Work With Pharma
    Learn More How Payers Want to Work With Pharma
    How to effectively engage US and EU payers You’re speaking to payers, but are they listening?  Do you really understand their needs and concerns?  Is your approach to payer negotiations getting your...
  • Medical Affairs in Orphan Drugs
    Learn More Medical Affairs in Orphan Drugs
    Orphan drugs: Is your medical affairs team leading the fray or lagging behind?  Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...
  • Pulling the Data Puzzle Together: Being Payer-Centric
    Learn More Pulling the Data Puzzle Together: Being Payer-Centric
    Mapping data with payer needs. How to solve the data puzzle.  Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...
  • Charting the Orphan Drug Development Pipeline
    Learn More Charting the Orphan Drug Development Pipeline
    Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...
  • Biosimilars in Emerging Markets (2017)
    Learn More Biosimilars in Emerging Markets (2017)
    Biosimilars: Make the most of high risk emerging market opportunities  Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...
  • Biosimilars: US Payer Perspectives (2017)
    Learn More Biosimilars: US Payer Perspectives (2017)
    Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out…  Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...
  • The Future of Biobetters
    Learn More The Future of Biobetters
    Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...
  • Overcoming Market Access Barriers to High Value Drugs
    Learn More Overcoming Market Access Barriers to High Value Drugs
    Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...
  • Real World Data Capabilities: Benchmarking Pharma Companies
    Learn More Real World Data Capabilities: Benchmarking Pharma Companies
    Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...
  • Biosimilars: European Payer Perspectives (2017)
    Learn More Biosimilars: European Payer Perspectives (2017)
    What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...
  • The Future of Medical Affairs
    Learn More The Future of Medical Affairs
    What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance.  And demands are set to...
  • Defending Against Biosimilars: Originator strategies
    Learn More Defending Against Biosimilars: Originator strategies
    Battle of the biologics: How to survive The onward march of biologics has shaped a brave new world for drug manufacturers with conflicting rules and regulations and an eclectic mix of individual players to contend with...
  • Value Added Services: Payer Perspectives (2016)
    Learn More Value Added Services: Payer Perspectives (2016)
    Payer viewpoint: What should value-added services be providing?   Getting close to payers and finding out exactly what they want from value-added services (VAS) has proved problematic for the pharmaceutical...
  • Biosimilars Education: Addressing a significant unmet need
    Learn More Biosimilars Education: Addressing a significant unmet need
    How to educate stakeholders about biosimilar benefits What information and data do physicians, payers and patients need about biosimilars? As the market expands and new therapeutic sectors come on stream, more...
  • Patient-centric pharma: Advancing the new business model
    Learn More Patient-centric pharma: Advancing the new business model
    The latest thinking on patient-centric structures and strategies  How are drug companies responding and adapting to the inexorable pull towards the patient-centric world? Patient centricity has been a buzz...

customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved